Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tixagevimab (AZD8895) is a humanized monoclonal antibody targeting the spike protein of SARS-CoV-2, with antiviral activity. It works by binding to the RBD and S protein domain, blocking the interaction with receptors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $247 | In Stock | |
5 mg | $645 | In Stock | |
10 mg | $987 | In Stock | |
25 mg | $1,530 | In Stock | |
50 mg | $1,980 | In Stock |
Description | Tixagevimab (AZD8895) is a humanized monoclonal antibody targeting the spike protein of SARS-CoV-2, with antiviral activity. It works by binding to the RBD and S protein domain, blocking the interaction with receptors. |
In vivo | Tixagevimab can be combined with Cilgavimab to form AZD7442, AZD7442 (2,4 or 16 mg/kg, intravenously) in hamsters infected with the G61 strain and Omicron variant, resulted in a dose-dependent decrease in lung infection titers and viral RNA levels in hamsters, and the infection titer at 16 mg/kg was significantly lower than that at 2 mg/kg. [1] |
Alias | AZD8895, AZD 8895 |
Cas No. | 2420564-02-7 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.